Johnson & Johnson has announced groundbreaking Phase 3 results for Tecvayli Multiple Myeloma Treatment, demonstrating its superiority over standard-of-care therapies in improving overall survival as early as the first relapse.
New data shows TECVAYLI plus DARZALEX FASPRO significantly improves survival outcomes for patients with relapsed/refractory multiple myeloma, setting the stage for a new standard of care.
The European Commission (EC) has granted a landmark approval for Johnson & Johnson’s DARZALEX® (daratumumab) as the first licensed treatment for patients with high-risk smouldering multiple myeloma (SMM). This decision marks a significant shift in the treatment paradigm for this precursor to active multiple myeloma, moving away from the traditional “watch and wait” approach to proactive, early therapeutic intervention.
Johnson & Johnson reports a 95% four-year progression-free survival rate using the DARZALEX FASPRO®-based regimen in transplant-eligible, newly diagnosed multiple myeloma patients who achieved sustained MRD negativity.
GSK’s Blenrep combinations have received a positive opinion from the CHMP for treating relapsed/refractory multiple myeloma, backed by strong Phase III trial results showing improved survival outcomes.
Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.
GSK’s Blenrep combinations have been approved in Japan for treating relapsed or refractory multiple myeloma, following strong Phase III trial results demonstrating improved survival outcomes.
CellCentric has secured $120 million in Series C funding to accelerate clinical development of Inobrodib, its first-in-class oral p300/CBP inhibitor for treating multiple myeloma. The investment will support upcoming Phase II/III trials and global expansion.
